6. Analysis of PAM50 breast cancer intrinsic Population: 270 FFPE samples from the DBCG trial 2014 prognostic subtypes and effect of gemcitabine Purpose: to evaluate whether the subtype identifies factors in advanced breast cancer patients patients with advanced breast cancer who would benefit from amongst Jorgenson et al gemcitabine plus docetaxel compared to docetaxel alone persons in a DBCG trial Results: Intrinsic subtypes were associated with randomised controlled trial progression (TTP, p = 0.0006) and overall survival (OS, p<0.0083). Response rate (complete plus partial response) did not differ Prognostic significantly among subtypes, nor between basal and non-basal level III-2 like types. For predictivity PAM50 subtypes were not – significantly different for TTP but for OS was significant. Basal-like type had an improved OS associated with gemcitabine plus docetaxel (Pinteraction = 0.0016). PAM50 subtype analysis - according to triple negative HER2 and ER status - showed no difference in treatment effect. 7. Analysis of Prediction of Late Distant Population: 2,137 FFPE samples from the ATAC and trials 2015 prognostic Recurrence After 5 Years of from post-menopausal women with ER/PR +ve who did not have factors Endocrine Treatment: A Combined recurrence after 5 years of endocrine treatment amongst Analysis of Patients From the Purpose: to assess the PAM50 ROR score for predicting distant persons in a Austrian Breast and Colorectal recurrence after 5 years follow-up randomised Cancer Study Group 8 and Arimidex, controlled trial Tamoxifen Alone or in Combination Results: CTS added more prognostic information for distant Randomized Trials Using the PAM50 recurrence 5 years after diagnosis than the ROR score in the Prognostic Risk of Recurrence score. overall population (univariable: LR = 94.12) and when added to χ2 level III-2 ROR score (bivariable: LR = 61.43). Agreement between ROR χ2 Sestak et al and CTS was weak (r = 0.36) ATAC trial: NCT00849030 ABCSG-8: NCT00291759
6. Analysis of prognostic factors amongst persons in a randomised controlled trial Prognostic level III-2 PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients Jorgenson et al DBCG trial Population: 270 FFPE samples from the DBCG trial Purpose: to evaluate whether the subtype identifies patients with advanced breast cancer who would benefit from gemcitabine plus docetaxel compared to docetaxel alone Results: Intrinsic subtypes were associated with (TTP, p = 0.0006) and overall survival (OS, p<0.0083). Response rate (complete plus partial response) did not differ significantly among subtypes, nor between basal and non-basal like types. For predictivity – PAM50 subtypes were not significantly different for TTP but for OS was significant. Basal-like type had an improved OS associated with gemcitabine plus docetaxel (Pinteraction = 0.0016). PAM50 subtype analysis - according to triple negative HER2 and ER status - showed no difference in treatment effect. 2014 7. Analysis of prognostic factors amongst persons in a randomised controlled trial Prognostic level III-2 Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence score. Sestak et al ATAC trial: NCT00849030 ABCSG-8: NCT00291759 Population: 2,137 FFPE samples from the ATAC and trials from post-menopausal women with ER/PR +ve who did not have recurrence after 5 years of endocrine treatment Purpose: to assess the PAM50 ROR score for predicting distant recurrence after 5 years follow-up Results: CTS added more prognostic information for distant recurrence 5 years after diagnosis than the ROR score in the overall population (univariable: LR χ2 = 94.12) and when added to ROR score (bivariable: LR χ2 = 61.43). Agreement between ROR and CTS was weak (r = 0.36) 2015 progression